Showing results (41-50 of 99) with videos related to

Sort By:
Pageof 10
British Journal of Clinical Pharmacology|May 17, 2020
Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort studyJacques Bouget, Frédéric Balusson, Maxime Maignan, et al.
Biochemical Pharmacology|December 23, 2025
Inflammatory protein signatures associated with high rivaroxaban exposureCatherine Feliu, Jean Escal, Cyril Leven, et al.
British Journal of Clinical Pharmacology|September 3, 2011
Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindioneKarine Lacut, Estelle Ayme-Dietrich, Lenaick Gourhant, et al.
Thrombosis and Haemostasis|July 24, 2003
Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive proteinKarine Lacut, Emmanuel Oger, Grégoire Le Gal, et al.
Haematologica|April 12, 2003
High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderlyEmmanuel Oger, Karine Lacut, Patrick Van Dreden, et al.
The European Respiratory Journal|July 29, 2017
Risk of recurrent venous thromboembolism in COPD patients: results from a prospective cohort studyRaphael Le Mao, Cécile Tromeur, Amélie Bazire, et al.
Journal of Thrombosis and Thrombolysis|July 7, 2021
Risk of recurrent venous thromboembolism and bleeding in patients with interstitial lung disease: a cohort studyRaphael Le Mao, Thomas Ropars, Cécile Tromeur, et al.
Thrombosis and Haemostasis|November 6, 2015
Serum levels of 25(OH)D are not associated with venous thromboembolism in the elderly population. A case-control studyMarion Andro, Aurélien Delluc, Marie-Pierre Moineau, et al.
Thrombosis Research|June 15, 2007
Fibrinogen Aalpha-Thr312Ala and factor XIII-A Val34Leu polymorphisms in idiopathic venous thromboembolismGrégoire Le Gal, Bénédicte Delahousse, Karine Lacut, et al.
Pageof 10